The climacteric period is the transitional phase during which a woman's body moves from the reproductive stage to the non-reproductive stage. It is a gradual process that spans several years. Within this broader phase occurs menopause, which is specifically defined as the permanent cessation of menstruation resulting from the loss of ovarian follicular activity.
Clinically, menopause is diagnosed retrospectively after 12 consecutive months of amenorrhea without any other pathological or physiological cause. The average age of natural menopause in West Africa and globally generally ranges between 45 and 55 years. Healthcare providers must distinguish between natural menopause, premature menopause (occurring before age 40), and induced menopause resulting from surgical removal of the ovaries or pelvic radiation therapy.
Female reproductive aging is primarily driven by the progressive decline in both the number and quality of ovarian follicles. Unlike males who produce sperm continuously, a female is born with her entire lifetime supply of oocytes, numbering in the millions at birth.
This cellular exhaustion means the ovaries can no longer mature eggs or produce adequate sex steroid hormones, leading directly to the shutdown of cyclical endometrial shedding.
As follicular reserves dwindle, the endocrine output of the ovaries changes dramatically. Estradiol, the primary and most potent estrogen produced by the ovaries, drops to very low levels. However, low-level estrogen conversion still occurs in peripheral adipose tissue and muscle from adrenal precursors.
Progesterone production nearly ceases altogether during the climacteric because functional corpus luteum formation stops due to anovulatory cycles. Conversely, pituitary gonadotropins—specifically Follicle-Stimulating Hormone (FSH) and Luteinizing Hormone (LH)—surge to exceptionally high levels because the loss of ovarian feedback removes the brakes on the pituitary gland.
The endocrine relationship between the hypothalamus, pituitary gland, and ovaries relies on a classic negative feedback loop. In younger years, ovarian hormones like estrogen and inhibin suppress the release of GnRH from the hypothalamus and gonadotropins from the anterior pituitary.
As the ovaries fail, they stop producing inhibin and adequate estrogen. Without these chemical suppressors, the pituitary gland loses its inhibitory signal. The anterior pituitary responds by pumping out massive amounts of FSH and LH in a futile attempt to stimulate the aging ovaries. This marked elevation of serum FSH is the standard laboratory marker used to confirm menopausal transition when clinical presentation is unclear.
The sudden fluctuation and eventual withdrawal of estrogen trigger acute vasomotor and neurochemical symptoms in many women. Vasomotor symptoms, commonly experienced as hot flashes and night sweats, stem from instability in the thermoregulatory center of the hypothalamus caused by altered neurotransmitter activity, particularly norepinephrine and serotonin.
Women also frequently report mood disturbances, sleep disruptions, fatigue, and cognitive fog. Additionally, estrogen receptors in the urogenital tract undergo atrophy, leading to vaginal dryness, dyspareunia, and urinary urgency, collectively referred to as the genitourinary syndrome of menopause.
Beyond immediate discomforts, long-term estrogen deprivation profoundly alters skeletal and vascular physiology. Estrogen normally promotes bone formation by restraining osteoclasts, the cells that break down bone tissue. When estrogen vanishes, osteoclast activity outpaces osteoblasts, leading to rapid bone mass loss and an increased risk of osteoporosis and fractures.
Cardiovascular health is also affected. Premenopausal estrogen offers protective vascular effects by maintaining healthy lipid profiles and promoting arterial elasticity. Postmenopause, women often experience an unfavorable shift in cholesterol—rising LDL and triglycerides with dropping HDL—increasing their long-term risk of cardiovascular disease.